Overview


The company is now raising $10M in the second round of Regulation A+ crowdfunding to support the growth of its portfolio of brands, develop new exciting products and pursue acquisition opportunities. All of this will provide our customers with safe and effective solutions to products and services that historically overuse toxic synthetic chemicals and addictive pharmaceutical products.

View Our Offering Circular

YEAR FOUNDED

2014

RAISED TO DATE

$1M+

INVESTORS

400+

MODEL

Portfolio

CURRENT PRICE PER SHARE

$.80

CURRENT MINIMUM INVESTMENT

$420

INDUSTRY

Pest Control, Healthcare, Emerging

PATH TO LIQUIDITY

IPO

Opportunity

The Problem

Nearly everyone on this planet is exposed to pesticides or has taken a pain relief pill, and science has proven the long-term health complications and diseases that can happen as a result. Yet, too few people are aware that alternative, Eco-friendly products, and methods exist in the market that do a similar job, with the same efficacy, but with zero negative impact on oneself or the environment.

Reports estimate that in the United States alone over 20 billion pounds of pesticides have been sprayed on our properties and food in just the last 20 years. Globally in the same timespan, this industry has generated over $1 Trillion in revenues. So, why are we all so exposed?

pesticide-graph

Millions of Pounds of Pesticides
Continue to be Sprayed Each Year

Historically, the use of synthetic chemicals in all of our food, drugs, products, and industries has been controlled by a small group of very large and powerful international corporations. These corporations hold patents and spend millions of dollars lobbying governments all over the world to make sure their products are deemed safe for use, even though the long-term effects from exposure have been proven to be unhealthful and dangerous.

Most of these synthetic chemicals contain strong toxic/poisonous chemicals with proven long-lasting, devastating carcinogenic effects. These compounds can take generations to become nascent in the environment. As more chemicals are sprayed or used in products, the build-up just keeps compounding the pollution that harms the environment.

We all know a family that has been impacted by the Opioid Public Health crisis the Pharmaceutical conglomerates have directly caused in this country by using similar unethical tactics of lobbying to get their addictive drugs in the hands of as many everyday Americans as possible. These addictive drugs that have been marketed for the use of everyday pain when science clearly proves the addictive nature of the chemicals used to make them. For a person born in 2017 the odds of dying from an Opioid Overdose is now higher than dying in a car accident.

Chemicals from plastics and pesticides are now beginning to be found in our groundwater and public drinking water supplies for the first time. No wonder numerous studies are now linking diseases such as Parkinson’s disease, asthma, cancer and reproductive dysfunction to chemical pesticides.

Opioid-Chart

29% OF ALL PEOPLE WHO ARE PRESCRIBED OPIOIDS END UP MISUSING THEM AND 12% OF  ALL PEOPLE PRESCRIBED OPIOIDS BECOME ADDICTED

The Med-X Solution

Med-X, Inc. has developed multiple all-natural plant-based brands of products that solve the same everyday issues people have been using chemicals to solve. Med-X is able to sell these products into the homes of everyday Americans through our partnerships with major retail and healthcare distributors as well as the leading international professional pest control distributors. The company is constantly marketing and educating the public about the dangers we face while at the same time offering real, proven effective, safe solutions. 

Through targeted marketing, national and international distribution venues and exposure through our media divisions, our high margin proprietary products are cutting through the noise and getting mainstream attention and sell-through. Med-X is also on the cutting edge of green product development by introducing new innovative topical and supplement products that will also become available to consumers in the future.

Our Mission

We would love to tell you that our green solution products and services will bring down big chemical and big pharma., but let’s be real, that is not going to happen. The point of this mission, in fact, is more about balance, transparency, and responsibility. Our goal here is to simply offer alternatives in markets that frankly have never embraced safe and effective natural options and as you are aware, our thinking and products are beginning to resonate.

Safe Is The New Normal

We are at the forefront of providing safer alternatives to big chemical and big pharma which will allow them to become more accountable. The consumer is demanding it. Times have changed. If you can offer a person two solutions to a problem, one is a chemical solution and one is a green solution, most Americans will now choose the green option as long as it has similar results. It is proven most Americans will actually pay substantially more for a safer option. Thankfully, the products Med-X produces, fall in line with middle America value and the company has sourced product ingredients and have focused on low-cost manufacturing techniques that enable the company to offer these products at favorable costs to consumers while holding higher margins for stakeholders.

In the past, there were little or no options for a homeowner to choose an effective green pesticide to be used in their home. Likewise, there were limited safe, drug-free options for truly relieving a migraine headache or everyday chronic pain. Now there are multiple options being offered by our Med-X Divisions and more that are in final development by Med-X scientists, doctors, and formulators. These products are proven effective in clinical trials and many are already in national and international distribution channels with sell-through driving growth.

products-group

Making a Difference, One Community at a Time.

Med-X, Inc. is an innovator and leader in developing all-natural and alternative solutions to the outdated poisonous chemicals and harmful pharmaceutical products, often used in pest control and pain management. Med-X incorporates best-in-class science, research and technology for manufacturing and service capabilities across pest control, pain management, aromatherapy, by primarily utilizing essential oil product development.

The company’s sales are represented by multiple commercial sales verticals and third-party service providers managed through various domestic and international distribution partners. Retail sales are currently conducted by over-the-counter pharmacy retailers and various e-commerce service providers. Med-X is also focused on educating the public by supporting its digital media platform The National Investor Network.

Our Brands

Med-X has built a portfolio of high margin commercial and consumer product brands as well as pest control services. These proven brands help drive the company’s current revenue. This portfolio strategy gives the company flexibility and power to scale up operations, and raise revenues in any sector by acquiring other like-minded brands who fit the company mission and would like the opportunity to grow together. The company is already in talks with several small to medium-sized companies who have shown interest in being a part of a bigger green movement.

The Med-X management team is motivated to continue to grow revenue and raise the capital needed to take the company public on a national exchange. Med-X has reserved the Nasdaq ticker symbol, (MXRX) and plans to offer its investors liquidity by entering the public market in the future.




image (1)-1

 

nature-cide-logo

The entire Nature-Cide line of products has 10 years of research and development behind them. All of these products have been proven effective in the field by licensed pest management professionals as well as by conducting third party laboratory efficacy tests. All of these products are registered in the 39 states that require EPA registration. These products are currently being utilized in major commercial and residential use nation wide in mainstream pest control, hospitality and agriculture. For SDS, Ingredients and Label information please visit each product product page.

 

thermal-aid-logo

Thermal-Aid all-natural products are clinically proven and patented therapeutic heating/cooling modality designed explicitly for the medical field, to reduce swelling and relieve various pain issues. Thermal-Aid products cover a wide variety of needs for patients in all age groups for a gamut of ailments including but not limited to arthritis, fibromyalgia, multiple sclerosis, migraines, back pain, and muscle aches. Thermal-Aid products can be found in various OTC pharmacy outlets and qualify for patient insurance reimbursement and FSA programs throughout the United States.

malibu-brands-logo

Malibu Brands is a premium, homeopathic lifestyle brand.  Malibu Brands' first product is the Pacific Pain Relief Cream, which is a proven, natural topical analgesic cream for the temporary relief of various pains including arthritis, joint, muscle, headache, and migraine pain. Malibu Brands is working to expand its product footprint with multiple products in development including a pain cream that utilizes plants as an ingredient. Additionally, the Malibu Brands division is planning to embark on designing a unique clothing line that uses alternative sustainable materials such as plant fiber and bamboo as they become readily available.

nin-logo

The National Investor Network is a hub for everyday investors to gather resources and information in regards to companies raising capital using public or private equity.  It serves as a portal with an extensive information base of companies and executives who are publicly raising capital or trading securities. This venue will be positioned to assist Med-X and other private and public companies with information dissemination to assist in their pursuits.

image-1

Going Forward Strategy

Nature-Cide Products & Services

Expand market positioning with commercial advertising and expanded distribution of the Nature-Cide product lines for continued sale in Commercial Pest Control, Hospitality, Janitorial, Transportation, Housing Authorities, School Districts, Turf-Care and Agriculture. We will also be preparing several Nature-Cide Ready to Use SKUs for consumer use to be primarily positioned in various Big Box retail.

The Nature-Cide service division plans to continue to grow it’s footprint in the Greater Los Angeles area as the management team continues to aggressively push to increase revenues and market share by acquiring existing pest control service companies and injecting the Nature-Cide products and Integrated Pest Management model into their existing book of business.

Thermal-Aid and Malibu Brands Products

Expand the market presence of Thermal-Aid in Pain Management sectors including insurance coverage segments for Physical Therapy, Flexible Spending, and Patient Care while continuing the expansion of its retail footprint within the OTC Pharmacy space.

Continue the placement of all products that fit within consumer retail with e-commerce expansion, including positioning the Malibu Brands assortment of products into the same position.

Product Positioning

National Pest Control And Healthcare Distribution

Nature-Cide is being used by a growing network of commercial customers including licensed pest control companies, like nationally positioned PestMaster Services, which provides pest control services in fourteen states. Nature-Cide currently supplies Univar Solutions, Target Specialty Products and its parent company “Rentokil Initial” in various regions including Asia and India.

The company plans to continue aggressively marketing within the Pest Control, Hospitality, Transportation, Agriculture, and Janitorial supply markets, while also pursuing the implementation of Nature-Cide in state and federal facilities throughout various regions in the United States.

pest-control-distribution-map

Market Overviews

Pain Management

The global pain management drug market is estimated to grow from $36.6 billion in 2014 to $44.3 billion by 2020. Pain is a distressing sensory and emotional feeling, which occurs due to tissue damage or illness. Various diseases, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer can cause pain. The duration of the pain varies from short-term known as acute pain to long-term referred to as chronic pain. Traditionally, the management of pain involves the reduction or treatment of pain using a particular set of drugs. Currently, 166 people die each day from an overdose by abusing prescription opiate pain medication. The need to improve service quality and safety for patients is expected to provide an impetus for growth in the pain management solution market.


Pest Management

The global insect pest control market is projected to grow from $12.4 billion in 2016 to $17.3 billion by 2022, according to research firm Markets and Markets. The insect pest control market is driven by government regulations on food hygiene, public health, environmental health, and growing public awareness. The need to improve service quality for customers
is expected to provide an impetus for growth in innovative pest control solutions. Lack of skilled technicians and delayed regulatory approval process for chemical products in different applications (such as residential, commercial, and industrial areas) have been considered restraining factors for the market and offer opportunities for products that fall under the less regulated FIFRA 25(b) Minimum Risk Pesticide category.

pest-control-graph@2x

 

pain-management-graph@2x

 

Agriculture Services

The Med-X management team is a major proponent of legalization on a federal level. As a member of the pest control community in emerging industries, the team hopes to expand its footprint in this emerging market by not only supplying pest control products to farmers but also legally participating in farming and manufacturing of innovative products.

Company management holds licenses for various types of applications for Pest Control and is trained and proficient in several types of agriculture. Management is proficient in supercritical CO2 extraction of all types of essential oils, and if and when the Federal Government eases rules and regulations on farming, sales, manufacturing and transportation, the company is positioned to enter farming and manufacturing of all types of innovative products.




Why Invest?

There is a very large demand for new effective all-natural solutions in both mainstream pest control and in the world of pharmaceuticals. The potential for the investor to prosper in these markets is there. These markets are long overdue for new ideas and innovations and opportunities to invest in these markets is rare and difficult to come by for the working-class American.

An investment in Med-X, is the opportunity to get in on the ground floor of a company that is already disrupting these markets with green options. We know that a larger portion of the market shares in these industries must move to the safer, greener side and we are sitting perfectly to address the needs of the markets as consumers continue to demand alternative options.

 



  • Traction

  • Growing Revenue

  • Distribution

  • Agriculture

  • Make A Difference

  • Portfolio Model

  • In-House Media

  • Path To Liquidity

History

2021-Med-X-Timeline

Our Team

 
david-toomey

Dr. David Toomey

CEO AND DIRECTOR

Dr. David Toomey’s professional life has been spent as a family physician for more than 24 years and a Hospice Medical Director for the last decade. Over his many years as a physician, Dr. Toomey has also worked as a clinical investigator developing and testing, in clinical trials for multiple companies including major pharmaceutical companies.

Matt_White

Matthew A. Mills

COO AND PRESIDENT

COO and President of Med-X, Inc. since inception, Matthew Mills is the company’s visionary, he utilizes and implements his vast experience and knowledge in product development, operations, business development, manufacturing, marketing and crowdfunding to position the company for short-term and long-term growth.

Ronald-Tchorzewski

Ronald J. Tchorzewski

CFO, DIRECTOR

CFO and Director Med-X, Inc. since inception, Ron Tchorzewski has over thirty-five years of experience in financial accounting for start-up and development companies, as well as reporting for publicly held companies from Silicon Valley and beyond. His chief financial officer level support, including business plan development, capital structure, and day-to-day accounting experience positions Med-X, Inc. for financial success.

jennifer-mills

Jennifer Mills

VICE PRESIDENT, CORPORATE SECRETARY, DIRECTOR

Jennifer Mills has been the Executive Vice President, Director and corporate secretary of Med-X, Inc. since its inception, Jennifer Mills has worked for multiple companies in her career as a high-level accounting liaison as well as in Human Resources and project management.

nick-phillips

Nick Phillips

VICE PRESIDENT, EDITOR-IN-CHIEF

Began his career in the Hollywood entertainment world and moved into digital marketing for multiple products in Los Angeles, which led him to the Company. He drives The Media Divisions. His skill set coupled with his dedication and attention to detail gives The Media Divisions solid leadership. 

Kurtz_White

Dr. Allan Kurtz

DIRECTOR

Dr. Allan Kurtz is board-certified in internal medicine and has owned and operated Allan Kurtz, a Professional Medical Corporation, since 1986. Dr. Kurtz has been the Medical Director of Warner Medical Center and the California Center of Longevity Medicine. He is also a long-time member of the American Osteopathic College of Internal Medicine.

Hyson_White

Dr. Morton Hyson

DIRECTOR

Dr. Morton Hyson is in private practice as a Board-certified Neurologist in Las Vegas, Nevada. He is also a Clinical Assistant Professor at Touro University in San Francisco, California, where he has been educating since September 2000. His professional affiliations include the American Medical Association, the American Academy of Neurology, the American Academy of Neurological and Orthopedic Surgeons, the American Headache Society.

Fred_White

Frederick Dashiell, Jr.

DIRECTOR

Mr. Dashiell has held various teaching positions at educational institutions such as Chapman University in Orange, California, University of California at Los Angeles and California Institute of Technology. Mr. Dashiell has also held various positions as a computer scientist as well as a research scientist in the private sector. Mr. Dashiell received a Bachelor of Science degree in physics from the University of North Carolina at Chapel Hill in 1963 and a Ph.D. in mathematics from the University of California at Berkeley in 1973.

Frequently Asked Questions


All Economic Value details, including future projections, employment numbers and or statistics, are sourced from The MB Fact Book. Produced by the MB Daily. Industry and revenue statistics are sourced from the ArcView Market Research Report.

What is Reg A+ Equity Crowdfunding?

In June 2015, the final Regulation A+ rules under Title IV of the JOBS Act of 2012 became effective, after approval by the Securities and Exchange Commission, paving the way for companies like Med-X, Inc. to raise up to $50 million from both accredited and non-accredited investors.

Med-X, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Updates

08/09/2021

NEW: Med-X, Inc. Secures $100 Million Expansion Capital Commitment from Global Emerging Markets (GEM)

LOS ANGELESAug. 6, 2021 /PRNewswire/ -- Today, Med-X, Inc. (MED-X) announced a $100 million capital commitment from GEM Global Yield, LLC SCS (GGY), a Luxembourg-based private alternative investment group. Under the agreement, GGY will provide MED-X with a Share Subscription Facility of up to $100 million for a 36-month term following the public listing of MED-X's common stock.

Med-X will control the timing and maximum number of drawdowns and under this agreement can put a drawdown notice for up to $10MM worth of shares on the first day of trading. Concurrent with a public listing Med-X will issue warrants to GEM to purchase up to 4.0% of the common stock of the company. Med-X's flagship division, Nature-Cide, has developed a line of all-natural professional pest control applications. One of its pest control solutions for Vector Control, is continuously being tested by third parties with astounding recorded results. The products are set for expansion, from major distribution partners in in various regions around the globe.

"GEM's equity investment solidifies our business model as well as our long-term financial goals while reinforcing and furthering our mission to the world stage", states founder and COO Matthew Mills. "So far, we've been very successful with self-underwriting our Regulation A+ Offering, which has generated investments from more than 3,600 individuals over the last 4 years. This new $100MM capital commitment should allow the Company to advance on its Mergers & Acquisitions strategy, while propelling the brands in a manner where our mission of "Making a difference every day" will move to a whole new level", states Mills.

About Med-X, Inc.

Med-X, Inc. is a Nevada corporation formed in February 2014 to support the fast-paced environmentally friendly green scene products and services sectors, with its Nature-Cide, Thermal-Aid and Malibu Brands divisions as well as the emerging hemp and cannabis industry through such activities as compound identification and extraction of the identified cannabidiol (CBD) compounds for the present medical industry demand. 
For more information regarding Med-X, Inc., please visit www.medx-rx.com, email info@medx-rx.com or call 818-349-2870

About The GEM Global Yield, LLC SCS Group

 

About GEM
Global Emerging Markets ('GEM') is a $3.4 billion, alternative investment group with offices in Paris, New York and Nassau (Bahamas). GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 440 transactions in 70 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities, and select venture investments. For more information: https://www.gemny.com

GEM Contact:

Jean-Luc Bonnefoy: jbonnefoy@gemny.com

 

Med-X Contact

Matthew Mills: matt@medx-rx.com

DISCLAIMER AND FORWARD-LOOKING STATEMENTS
The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the Regulation A+ Offering Circular Securities Exchange Commission filings before making any investment in the Company. 

This article may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

SOURCE Med-X, Inc.

Read More »


05/21/2021

Med-X, Inc. Management Team Signs $86 Million Dollar Non-Binding Term Sheet to Bolster Long Term Growth and Prepare the Company for a Potential Public Listing

In this exciting Company update, COO and President, Matthew Mills informs shareholders on the status of several international deals, status of ecommerce growth, capital raising and announces an exciting signing of the Company's first non-binding Term Sheet with an investment bank for an 86 Million dollar equity drawdown, to support the Company’s growth initiatives, if and when the Company lists on a public exchange. 

   

Growth in our digital ecommerce sales efforts continues its pace forward. New initiatives have recently been executed to continue to bolster B2C sales including the approval from Walmart Marketplace to enter the Walmart Fulfillment program. 

Walmart is very selective when it comes to approving brands and companies to be included in this program, so we feel very confident that our products and customer service is making a difference in our customers' lives. Walmart is recognizing us, which is great news for our brands.  

Walmart advertises to its fulfillment partners that customers should expect a 20% to 40% increase in sales by simply entering the program. We will keep you updated on this front in future updates as our team continues to dial this all in. 

Progress also continues to be made on our international Nature-Cide positioning as the labels are currently under review to get approved by the Mexican and Australian governmental authorities. Products have already shipped to Terminix in the Caribbean and Antigua. The compliance and approval processes are critical for our growth internationally but our partners have a solid track record of bringing in new products, and we feel really good about the coming months as we continue to push through the red tape. 

Matthew continues to speak with dozens of interested investment entities including VC’s, Angel investors, Family Offices and Investment Banks. Our partners at New Chip as well as our new broker-dealer, The Dalmore Group, have been actively making strong recommendations and introductions as the management team works tirelessly to find the right fit to assist our efforts to potentially take the Company to the public market. 

Matthew has also initially agreed to an 86 Million dollar non-binding term sheet with a large investment bank who is committed to seeing our Company grow and bolster revenue once the Company is listed.

At this point, the Company fits all the criteria to list on the Nasdaq except for one item. We need an additional $4 million dollars in the bank to fully qualify. Many of our Accredited investors have recognized this opportunity and they have stepped up in a big way to support this mission. 

This money is required so the Company can bridge the gap from private to public, as Matthew explains in the video.

“We are finally in a position where our business is of interest to the investment banking community, and we will continue pushing to line up the right partners. One thing we have learned over the years is to have as many irons in the fire as possible on all fronts. It’s inevitable that some of the relationships will flourish, and others will fizzle and not perform as expected. So, the only way we can move forward is to build an abundance of relationships amongst all of the inner workings of our business, until we find all the right performers,” states Matthew.    

We are hopeful that all of our shareholders will also recognize this opportunity and spread the word by telling their friends, family and co-workers about our Company and how they can also get involved and get in on the ground floor before we potentially file for a listing on a public exchange. 

As Matthew also says in the video, this is an exciting time and all of your support and the hard work from our team has really set the Company up for success and is setting a path for our goals. We would never be in this position without all the support from each and every one of our shareholders. 

We thank you. We are all so grateful to have such an amazing group of people connected to this Company who support all of our work. 

Also, please double-check your investor dashboard to make sure everything is matching up with your records. As we get closer to our end goal it will be critical that your contact information and investment information is accurate. Contact us if you notice any discrepancies. 

SEC FIling - https://www.sec.gov/Archives/edgar/data/1620704/000147793221002683/medx_1k.htm

Thank you very much.

Med-X Team

DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

Read More »


03/05/2021

Momentum for Med-X Continues to Grow on Multiple Fronts as Investment Banks Get More Involved

In this company video update President and COO, Matthew Mills discusses the company's continued progress with E-Commerce distribution as well as the momentum that continues building with multiple investment banking opportunities including a new promising investment banker / broker-dealer relationship.

Read More »


01/23/2021

Update: 1-22-2021 - Nature-Cide Begins Movement Into Mexico and Australia

In this video update on January 22,  2021, COO and President, Matthew Mills reports to all shareholders on the revenue momentum that is carrying over into 2021. He explains in detail why the Company is having its best January in its history as well as discusses some exciting news in regarding the details, including our new relationships that are bringing the Nature-Cide products into Mexico, Australia, Sri Lanka and the Caribbean. 

There are a lot of moving parts with this business, so please watch the video and check the news and updates section in your investor dashboard regularly, as communications will be increasing as the Company moves forward.  

We are excited to report that revenue is exceeding our expectations already this year. This is the best start to a year the Company has had and we are hopeful this is setting the tone for the rest of the year.

Read More »


12/29/2020

12-28-2020 - Med-X, Inc. Grows in 2020 with Essential Products, Reaches 1 Million in Revenue and Gears up to Continue Expansion in 2021

In this video update, COO and President, Matthew Mills reviews the year-end Company progress and outlines how this momentum will potentially set the Company up in 2021.

2020 was a challenging year for everyone including Med-X. We faced all the challenges head-on and even during this global pandemic, of the likes few living people have ever endured, we still balanced the Company and grew revenue to over 1 million dollars. 

Read More »